{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-070382","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-06-22T12:10:21+00:00","discovered_at":"2026-06-22T12:15:00.268458+00:00","generated_at":"2026-06-22T12:15:27.603619+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Allarity announces Trial-in-Progress poster for Phase 2 stenoparib at ESMO Gynaecological Cancers Congress 2026","bullets":["Poster outlines Phase 2 trial of stenoparib (dual PARP/WNT inhibitor) for platinum-resistant ovarian cancer.","Presented by Principal Investigator Dr. Kathleen N. Moore, expert in advanced ovarian cancer.","No new clinical data reported; Trial-in-Progress design describes study rationale and design only.","Conference held June 17–19, 2026 in Copenhagen, Denmark; poster displayed June 18, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-070382","json":"https://secwatch.observer/filing/0001213900-26-070382.json","markdown":"https://secwatch.observer/filing/0001213900-26-070382.md","text":"https://secwatch.observer/filing/0001213900-26-070382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/0001213900-26-070382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/ea0295409-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:15:27.603619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}